Nintx is featured in Valor Econômico’s article in Brazil’s innovation sector

By Lilian Caramel - For Valor Econômico 02/26/2025

Radical innovation is gaining momentum with the proliferation of biotechnology startups, which focus on the analysis and diagnosis of treatments, therapies and new products. The newcomer Nintx, headquartered in the Techno Park of Campinas (SP), conducts research projects for new medicines for multifactorial diseases and supplements based on native plants. The first launch of the biotech, which is restricted to R&D, will take place in the coming months through a partner laboratory - a formula for gluten-intolerant patients. The company plans to develop eight nutraceuticals by 2027. "We will develop therapies capable of helping doctors modulate the intestinal microbiome. Several pathologies are associated with the imbalance of the bacterial flora of the intestine", says Nintx's CEO, Stephani Saverio.

To have access to the full content, check us out on LinkedIn.

https://www.linkedin.com/posts/nintx_valor-economico-26022025-activity-7300616454222053381-arM5?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAAUL6oB6dOVqNQ7Ria1q2TMTlnb4Jf7Jwk